Keith F. Fournier, M.D.

Peer-Reviewed Articles

1. Seldomridge AN, White MG, Scally C, Royal RE, Routbort M, Iorgulescu JB, Overman MJ, Lee SM, Foo WC, Taggart MW, Song Y, Mansfield PF, Fournier KF, Shen JP, Helmink BA. ASO Visual Abstract: Clinicopathologic and Molecular Characteristics of High-Grade Appendiceal Mucinous Neoplasms. Ann Surg Oncol, 2025. e-Pub 2025. PMID: 41366166.
2. Seldomridge AN, White MG, Scally C, Royal RE, Routbort M, Iorgulescu J, Overman MJ, Lee SM, Foo WC, Taggart MW, Song Y, Mansfield PF, Fournier KF, Shen JP, Helmink BA. Clinicopathologic and Molecular Characteristics of High-Grade Appendiceal Mucinous Neoplasms. Ann Surg Oncol, 2025. e-Pub 2025. PMID: 41225239.
3. Marincola Smith P, Lie JJ, Seldomridge A, Galbraith NJ, Ramamurthy J, Song Y, Helmink BA, Mansfield PF, Fournier KF, White MG. Repeat Cytoreductive Surgery for Colorectal Cancer Metastatic to the Peritoneal Cavity. Ann Surg Oncol, 2025. e-Pub 2025. PMID: 41015624.
4. Smith PM, Seldomridge A, Chiang YJ, White MG, Song Y, Scally C, Mansfield PF, Fournier KF, Helmink BA. Outcomes following diagnostic laparoscopy in patients with peritoneal carcinomatosis deemed ineligible for cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) due to disease burden. Surg Oncol Insight 2(2), 2025. e-Pub 2025. PMID: 40740309.
5. Ashraf Ganjouei A, Wang J, Yi C, Romero-Hernandez F, Alseidi A, Abbott D, Zafar SN, Fournier KF, Staley CA, Dineen S, Raoof M, Bartlett DL, Cloyd JM, Choudry HM, Adam MA. Predicting Severe Postoperative Complications after CRS-HIPEC: An Externally Validated Machine-Learning Tool. World J Surg 49(6):1546-1554, 2025. e-Pub 2025. PMID: 40295427.
6. Ayabe RI, Beaty K, Newhook TE, Cao HST, Tzeng CD, Helmink BA, Uppal A, Vauthey JN, Fournier KF, White MG. Incomplete Cytoreduction and Need for Major Hepatectomy Predict Shorter Survival in Patients Undergoing Combined Cytoreductive Surgery and Hepatectomy for Metastatic Colorectal Cancer. Ann Surg Oncol. e-Pub 2024. PMID: 38971956.
7. Fackche NT, Schmocker RK, Nudotor R, Kubi B, Cloyd JM, Grotz TE, Fournier KF, Dineen SP, Veerapong J, Baumgartner JM, Clarke CN, Patel SH, Wilson GC, Lambert LA, Pokrzywa C, Abbott DE, Lee B, Staley CA, Zaidi MY, Johnston FM, Greer JB. Preoperative CA 19-9 Predicts Disease Progression in Colorectal Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: An Analysis from the US HIPEC Collaborative. Ann Surg Oncol 31(5):3314-3324, 2024. e-Pub 2024. PMID: 38310181.
8. Belmont E, Bansal VV, Yousef MMG, Zeineddine MA, Su D, Dhiman A, Liao CY, Polite B, Eng OS, Fournier KF, White MG, Turaga KK, Shen JP, Shergill A. Multi-Institutional Study Evaluating the Role of Circulating Tumor DNA in the Management of Appendiceal Cancers. JCO Precis Oncol 8:e2300531, 2024. e-Pub 2024. PMID: 38723230.
9. Yousef A, Yousef M, Zeineddine MA, More A, Fanaeian M, Chowdhury S, Knafl M, Edelkamp P, Ito I, Gu Y, Pattalachinti V, Naini ZA, Zeineddine FA, Peterson J, Alfaro K, Foo WC, Jin J, Bhutiani N, Higbie V, Scally CP, Kee B, Kopetz S, Goldstein D, Strach M, Williamson A, Aziz O, Barriuso J, Uppal A, White MG, Helmink B, Fournier KF, Raghav KP, Taggart MW, Overman MJ, Shen JP. Serum Tumor Markers and Outcomes in Patients With Appendiceal Adenocarcinoma. JAMA Netw Open 7(2):e240260, 2024. e-Pub 2024. PMID: 38416491.
10. Pattalachinti VK, Ito I, Chowdhury S, Yousef A, Gu Y, Gunes BB, Salle ER, Taggart M, Fournier K, Fowlkes NW, Shen JP. Peritoneal Microenvironment Promotes Appendiceal Adenocarcinoma Growth: A Multi-omics Approach Using Patient-Derived Xenografts. Mol Cancer Res. e-Pub 2024. PMID: 38226984.
11. Bhutiani N, Grotz TE, Concors SJ, White MG, Helmink BA, Raghav KP, Taggart MW, Beaty KA, Royal RE, Overman MJ, Matamoros A, Scally CP, Rafeeq S, Mansfield PF, Fournier KF. Repeat Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Recurrent Mucinous Appendiceal Adenocarcinoma: A Viable Treatment Strategy with Demonstrable Benefit. Ann Surg Oncol 31(1):614-621, 2024. e-Pub 2024. PMID: 37872456.
12. Florissi I, Radomski SN, Shou B, Cloyd JM, Kim A, Grotz T, Fournier K, Baumgartner JM, Lambert L, Abbott DE, Schwartz P, Staley CA, Clarke C, Dineen S, Patel SH, Wilson GC, Raoof M, Johnston FM, Greer JB. Weekend Discharge Is Not Associated With Increased Readmission After Hyperthermic Intraperitoneal Chemotherapy. J Surg Res 293:403-412, 2024. e-Pub 2024. PMID: 37806228.
13. SenthilKumar G, Merrill J, Maduekwe UN, Cloyd JM, Fournier K, Abbott DE, Zafar N, Patel S, Johnston F, Dineen S, Baumgartner J, Grotz TE, Maithel SK, Raoof M, Lambert L, Hendrix R, Kothari AN. Prediction of Early Recurrence Following CRS/HIPEC in Patients With Disseminated Appendiceal Cancer. J Surg Res 292:275-288, 2023. e-Pub 2023. PMID: 37666090.
14. White MG, Bhutiani N, Helmink BA, Taggart M, Foo WC, Mansfield PF, Fournier KF, Scally CP. ASO Visual Abstract: Treatment Variation and Long-Term Outcomes of Low-Grade Appendiceal Neoplasms. Ann Surg Oncol 30(13):8176, 2023. e-Pub 2023. PMID: 37728822.
15. White MG, Bhutiani N, Helmink BA, Taggart M, Foo WC, Mansfield PF, Fournier KF, Scally CP. Treatment Variation and Long-Term Outcomes of Low-Grade Appendiceal Neoplasms. Ann Surg Oncol 30(13):8138-8143, 2023. e-Pub 2023. PMID: 37702905.
16. Winicki NM, Radomski SN, Florissi IS, Cloyd JM, Gutta G, Grotz TE, Scally CP, Fournier KF, Dineen SP, Powers BD, Veerapong J, Baumgartner JM, Clarke CN, Kothari AN, Maduekwe UN, Patel SH, Wilson GC, Schwartz P, Varley PR, Raoof M, Lee B, Malik I, Johnston FM, Greer JB. ASO Visual Abstract: Neighborhood Level Socioeconomic Disadvantage Predicts Outcomes in Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Malignancy. Ann Surg Oncol 30(13):8178-8179, 2023. e-Pub 2023. PMID: 37768415.
17. Bhutiani N, White MG, Kim BJ, Scally CP, Helmink BA, Mansfield PF, Fournier KF, Royal RE. Decreasing Environmental Operating Room Chemotherapy Levels Following Heated Intraperitoneal Chemotherapy (HIPEC) Through Implementation of Standard Protocols. Ann Surg Oncol 30(12):6981-6982, 2023. e-Pub 2023. PMID: 37624514.
18. Winicki NM, Radomski SN, Florissi IS, Cloyd JM, Gutta G, Grotz TE, Scally CP, Fournier KF, Dineen SP, Powers BD, Veerapong J, Baumgartner JM, Clarke CN, Kothari AN, Maduekwe UN, Patel SH, Wilson GC, Schwartz P, Varley PR, Raoof M, Lee B, Malik I, Johnston FM, Greer JB. Neighborhood-Level Socioeconomic Disadvantage Predicts Outcomes in Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Malignancy. Ann Surg Oncol 30(12):7840-7847, 2023. e-Pub 2023. PMID: 37620532.
19. Ito I, Yousef AMG, Chowdhury S, Dickson PN, Naini ZA, White MG, Fleten KG, Flatmark K, Fournier KF, Fowlkes NW, Shen JP. Intraperitoneal Paclitaxel Is a Safe and Effective Therapeutic Strategy for Treating Mucinous Appendiceal Adenocarcinoma. Cancer Res 83(19):3184-3191, 2023. e-Pub 2023. PMID: 37433032.
20. Yousef A, Yousef M, Zeineddine M, More A, Chowdhury S, Knafl M, Edelkamp P, Ito I, Gu Y, Pattalachinti V, Naini ZA, Zeineddine F, Peterson J, Alfaro K, Foo WC, Jin J, Bhutiani N, Higbie V, Scally C, Kee B, Kopetz S, Goldstein D, Uppal A, White MG, Helmink B, Fournier K, Raghav K, Taggart M, Overman MJ, Shen JP. The Clinical Significance of CEA, CA19-9, and CA125 in Management of Appendiceal Adenocarcinoma. medRxiv, 2023. e-Pub 2023. PMID: 37745596.
21. SenthilKumar G, Kothari AN, Maduekwe UN, Fournier K, Abbott DE, Wilson GC, Patel SH, Greer J, Johnston F, Dineen SP, Powers BD, Baumgartner J, Veerapong J, Leiting J, Grotz TE, Maithel SK, Staley C, Raoof M, Lambert L, Lee A, Kim A, Cloyd JM, Mogal H. ASO Visual Abstract: Validation of the AJCC 8th Edition Staging System for Disseminated Appendiceal Cancer Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy-A Multi-institutional Analysis. Ann Surg Oncol 30(9):5756-5757, 2023. e-Pub 2023. PMID: 37423927.
22. SenthilKumar G, Kothari AN, Maduekwe UN, Fournier K, Abbott DE, Wilson GC, Patel SH, Greer J, Johnston F, Dineen SP, Powers BD, Baumgartner J, Veerapong J, Leiting J, Grotz TE, Maithel SK, Staley C, Raoof M, Lambert L, Lee A, Kim A, Cloyd JM, Mogal H. Validation of the AJCC 8th Edition Staging System for Disseminated Appendiceal Cancer Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: A Multi-institutional Analysis. Ann Surg Oncol 30(9):5743-5753, 2023. e-Pub 2023. PMID: 37294386.
23. Shen JP, Yousef AM, Zeineddine FA, Zeineddine MA, Tidwell RS, Beaty KA, Scofield LC, Rafeeq S, Hornstein N, Lano E, Eng C, Matamoros A, Foo WC, Uppal A, Scally C, Mansfield P, Taggart M, Raghav KP, Overman MJ, Fournier K. Efficacy of Systemic Chemotherapy in Patients With Low-grade Mucinous Appendiceal Adenocarcinoma: A Randomized Crossover Trial. JAMA Netw Open 6(6):e2316161, 2023. e-Pub 2023. PMID: 37261831.
24. Conley AB, Fournier KF, Sood AK, Frumovitz M. Secondary Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy for Advanced or Recurrent Mucinous Ovarian Cancer. Obstet Gynecol 141(5):1019-1023, 2023. e-Pub 2023. PMID: 37023452.
25. Ito I, Yousef AM, Dickson PN, Naini ZA, White MG, Fleten KG, Flatmark K, Fournier KF, Fowlkes NW, Shen JP. Antitumor activity of intraperitoneal paclitaxel in orthotopic patient-derived xenograft models of mucinous appendiceal adenocarcinoma. bioRxiv, 2023. e-Pub 2023. PMID: 36993681.
26. Beal EW, Srinivas S, Shen C, Kim A, Johnston FM, Greer J, Abbott DE, Pokrzywa C, Raoof M, Grotz TE, Leiting JL, Fournier K, Dineen S, Powers B, Veerapong J, Kothari A, Maduekew U, Maithel S, Wilson GC, Patel SH, Lambert L, Abdel-Misih S, Cloyd JM. ASO Visual Abstract: Conditional Survival After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Surface Malignancies: An Analysis from the US HIPEC Collaborative. Ann Surg Oncol 30(3):1850-1851, 2023. e-Pub 2023. PMID: 36418799.
27. Aiken T, Hu CY, Uppal A, Francescatti AB, Fournier KF, Chang GJ, Zafar SN. Peritoneal recurrence after resection for Stage I-III colorectal cancer: A population analysis. J Surg Oncol 127(4):678-687, 2023. e-Pub 2023. PMID: 36519668.
28. Beal EW, Srinivas S, Shen C, Kim A, Johnston FM, Greer J, Abbott DE, Pokrzywa C, Raoof M, Grotz TE, Leiting JL, Fournier K, Dineen S, Powers B, Veerapong J, Kothari A, Maduekew U, Maithel S, Wilson GC, Patel SH, Lambert L, Abdel-Misih S, Cloyd JM. Conditional Survival Following Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Surface Malignancies: An Analysis from the US HIPEC Collaborative. Ann Surg Oncol 30(3):1840-1849, 2023. e-Pub 2023. PMID: 36310315.
29. Erstad DJ, Robinson KA, Beaty K, Rafeeq S, Chiang YJ, Raghav K, Shen JP, Overman MJ, Foo WC, Taggart MW, Mansfield PF, Royal RE, Fournier KF, Scally CP. Prognostic significance of acellular mucin in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) for appendiceal neoplasms. Langenbecks Arch Surg 408(1):110, 2023. e-Pub 2023. PMID: 36853519.
30. Kubi B, Nudotor R, Fackche N, Rowe J, Cloyd JM, Ahmed A, Grotz TE, Fournier K, Dineen S, Veerapong J, Baumgartner JM, Clarke C, Patel SH, Dhar V, Lambert L, Abbott DE, Pokrzywa C, Raoof M, Lee B, Zaidi MY, Maithel SK, Johnston FM, Greer JB. Influence of insurance status on the postoperative outcomes of cytoreductive surgery and HIPEC. J Surg Oncol. e-Pub 2022. PMID: 36468401.
31. Turner KM, Morris MC, Delman AM, Hanseman D, Johnston FM, Greer J, Walle KV, Abbott DE, Raoof M, Grotz TE, Fournier K, Dineen S, Veerapong J, Maduekwe U, Kothari A, Staley CA, Maithel SK, Lambert LA, Kim AC, Cloyd JM, Wilson GC, Sussman JJ, Ahmad SA, Patel SH. Do Lymph Node Metastases Matter in Appendiceal Cancer with Peritoneal Carcinomatosis? A US HIPEC Collaborative Study. J Gastrointest Surg 26(12):2569-2578, 2022. e-Pub 2022. PMID: 36258061.
32. Bhutiani N, Cox DM, Robinson KA, Kim BJ, Mansfield PF, Fournier KF, White MG. Stapled Versus Hand-Sewn Anastomosis in Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy. J Gastrointest Surg 26(11):2365-2367, 2022. e-Pub 2022. PMID: 35676459.
33. Malpica A, Euscher ED, Marques-Piubelli ML, Miranda RN, Raghav KP, Fournier KF, Ramalingam P. Localized Malignant Peritoneal Mesothelioma (LMPeM) in Women: A Clinicopathologic Study of 18 Cases. Am J Surg Pathol 46(10):1352-1363, 2022. e-Pub 2022. PMID: 35713639.
34. Beal EW, Chen JC, Kim A, Johnston FM, Abbott DE, Raoof M, Grotz TE, Fournier K, Dineen S, Veerapong J, Clarke C, Staley C, Patel SH, Lambert L, Cloyd JM. Is Cytoreductive Surgery-Hyperthermic Intraperitoneal Chemotherapy Still Indicated in Patients With Extraperitoneal Disease?. J Surg Res 277:269-278, 2022. e-Pub 2022. PMID: 35525209.
35. DiPeri, TP, Newhook, TE, Day, RW, Chiang, YJ, Dewhurst, WL, Arvide, EM, Bruno, M, Scally, CP, Roland, CL, Katz, MH, Vauthey, JN, Chang, GJ, Badgwell, BD, Perrier, ND, Grubbs, EG, Lee, JE, Tzeng, CD, Bednarski, BK, Chen, IB, Comeaux, RJ, Cox, DM, Feig, BW, Fisher, SB, Fournier, KF, Ghebremichael, SJ, Gibson, H, Gourmelon, NC, Graham, PH, Hancher-Hodges, S, Hunt, KK, Ikoma, N, Ivey MPAS, SL, Keung, EZ, Ledet, CR, Limmer, AR, Mansfield, PF, Mayon, L, Messick, C, Popat, KU, Rajkot MPAS, NF, Rodriguez-Bigas, MA, Santos, DA, Skibber, JM, Speer, BB, Soliz, J, Tillman, MM, Torres, KE, Van Meter, A, Williams, UU, You, YN. A prospective feasibility study evaluating the 5x-multiplier to standardize discharge prescriptions in cancer surgery patients. Surgery Open Science 9:51-57, 2022. e-Pub 2022. PMID: 35663797.
36. Deng H, Eftekhari Z, Carlin C, Veerapong J, Fournier KF, Johnston FM, Dineen SP, Powers BD, Hendrix R, Lambert LA, Abbott DE, Vande Walle K, Grotz TE, Patel SH, Clarke CN, Staley CA, Abdel-Misih S, Cloyd JM, Lee B, Fong Y, Raoof M. Development and Validation of an Explainable Machine Learning Model for Major Complications After Cytoreductive Surgery. JAMA Netw Open 5(5):e2212930, 2022. e-Pub 2022. PMID: 35612856.
37. Guerra-Londono CE, Owusu-Agyemang P, Corrales G, Rofaeil MM, Feng L, Fournier K, Cata JP. Risk of Intraoperative Hyperthermia and Outcomes in Adults Undergoing Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC). Ann Surg Oncol 29(3):2089-2099, 2022. e-Pub 2022. PMID: 34704181.
38. Guerra-Londono CE, Owusu-Agyemang P, Corrales G, Rofaeil MM, Feng L, Fournier K, Cata JP. ASO Author Reflections: Predicting Hyperthermia and Its Effect in Patients with Peritoneal Surface Malignancies. Ann Surg Oncol 29(3):2100-2101, 2022. e-Pub 2022. PMID: 34713370.
39. Uppal A, Helmink B, Grotz TE, Konishi T, Fournier KF, Nguyen S, Taggart MW, Shen JP, Bednarski BK, You YN, Chang GJ. What is the Risk for Peritoneal Metastases and Survival Afterwards in T4 Colon Cancers?. Ann Surg Oncol. e-Pub 2022. PMID: 35307803.
40. Nizam W, Fackche N, Pessoa B, Kubi B, Cloyd JM, Grotz T, Fournier K, Dineen S, Veerapong J, Baumgartner JM, Clarke C, Patel SH, Wilson GC, Lambert L, Abbott DE, Vande Walle KA, Lee B, Raoof M, Maithel SK, Russell MC, Zaidi MY, Johnston FM, Greer JB. Prognostic Significance of Preoperative Tumor Markers in Pseudomyxoma Peritonei from Low-Grade Appendiceal Mucinous Neoplasm: a Study from the US HIPEC Collaborative. J Gastrointest Surg 26(2):414-424, 2022. e-Pub 2022. PMID: 34506026.
41. Malpica A, Euscher ED, Marques-Piubelli ML, Miranda RN, Fournier KF, Raghav KP, Ramalingam P. Malignant Peritoneal Mesothelioma Associated With Endometriosis: A Clinicopathologic Study of 15 Cases. Int J Gynecol Pathol 41(1):59-67, 2022. e-Pub 2022. PMID: 33577225.
42. Raghav K, Liu S, Overman MJ, Willett AF, Knafl M, Fu SC, Malpica A, Prasad S, Royal RE, Scally CP, Mansfield PF, Wistuba II, Futreal AP, Maru DM, Solis Soto LM, Parra Cuentas ER, Chen H, Villalobos P, Verma A, Mahvash A, Hwu P, Cortazar P, McKenna E, Yun C, Dervin S, Schulze K, Darbonne WC, Morani AC, Kopetz S, Fournier KF, Woodman SE, Yao JC, Varadhachary GR, Halperin DM. Efficacy, Safety and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma. Cancer Discov 11(11):2738-2747, 2021. e-Pub 2021. PMID: 34261675.
43. Guerra-London CE, Owusu-Agyemang P, Corrales G, Rofaeil MM, Feng L, Fournier K, Cata JP. ASO Visual Abstract: Risk of Intraoperative Hyperthermia and Outcomes in Adults Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy. Ann Surg Oncol. e-Pub 2021. PMID: 34729655.
44. Fackche N, Schmocker RK, Kubi B, Cloyd JM, Ahmed A, Grotz T, Leiting J, Fournier K, Lee AJ, Powers B, Dineen S, Veerapong J, Baumgartner JM, Clarke C, Gamblin TC, Patel SH, Dhar V, Hendrix RJ, Lambert L, Abbott DE, Pokrzywa C, Lafaro K, Lee B, Zaidi MY, Maithel SK, Johnston FM, Greer JB. The Utility of Preoperative Tumor Markers in Peritoneal Carcinomatosis from Primary Appendiceal Adenocarcinoma: an Analysis from the US HIPEC Collaborative. J Gastrointest Surg 25(11):2908-2919, 2021. e-Pub 2021. PMID: 33634422.
45. Cata JP, Fournier K, Corrales G, Owusu-Agyemang P, Soliz J, Bravo M, Wilks J, Van Meter A, Hernandez M, Gottumukkala V, group HS. The Impact of Thoracic Epidural Analgesia Versus Four Quadrant Transversus Abdominis Plane Block on Quality of Recovery After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy Surgery: A Single-Center, Noninferiority, Randomized, Controlled Trial. Ann Surg Oncol 28(9):5297-5310, 2021. e-Pub 2021. PMID: 33534044.
46. Raghav K, Liu S, Overman M, Morani A, Willette A, Fournier K, Varadhachary G. Clinical Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Malignant Peritoneal Mesothelioma. JAMA Netw Open 4(8):e2119934, 2021. e-Pub 2021. PMID: 34357397.
47. Kubi B, Nudotor R, Fackche N, Nizam W, Cloyd JM, Grotz TE, Fournier KF, Dineen SP, Powers BD, Veerapong J, Baumgartner JM, Clarke CN, Patel SH, Lambert LA, Abbott DE, Vande Walle KA, Raoof M, Lee B, Maithel SK, Staley CA, Johnston FM, Greer JB. Impact of Perioperative Blood Transfusions on Outcomes After Hyperthermic Intraperitoneal Chemotherapy: A Propensity-Matched Analysis. Ann Surg Oncol 28(8):4499-4507, 2021. e-Pub 2021. PMID: 33507449.
48. Bhamidipati D, Colina A, Hwang H, Wang H, Katz M, Fournier K, Serpas V, Thomas J, Sun R, Wolff RA, Raghav K, Overman MJ. Metastatic small bowel adenocarcinoma: role of metastasectomy and systemic chemotherapy. ESMO Open 6(3):100132, 2021. e-Pub 2021. PMID: 33940348.
49. Wiseman JT, Abdel-Misih S, Beal EW, Zaidi MY, Staley CA, Grotz T, Leiting J, Fournier K, Lee AJ, Dineen S, Powers B, Veerapong J, Baumgartner JM, Clarke C, Patel SH, Dhar V, Hendrix RJ, Lambert L, Abbott DE, Pokrzywa C, Raoof M, Eng O, Fackche N, Greer J, Pawlik TM, Cloyd JM. A multi-institutional analysis of Textbook Outcomes among patients undergoing cytoreductive surgery for peritoneal surface malignancies. Surg Oncol 37:101492, 2021. e-Pub 2021. PMID: 33465587.
50. Scally CP, Fournier KF, Mansfield PF. Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery. JAMA Surg 156(3):e206364, 2021. e-Pub 2021. PMID: 33502464.
51. Lee RM, Gamboa AC, Turgeon MK, Zaidi MY, Kimbrough C, Leiting J, Grotz T, Lee AJ, Fournier K, Powers B, Dineen S, Baumgartner JM, Veerapong J, Mogal H, Clarke C, Wilson G, Patel S, Hendrix R, Lambert L, Pokrzywa C, Abbott DE, LaRocca CJ, Raoof M, Greer J, Johnston FM, Staley CA, Cloyd JM, Maithel SK, Russell MC. A novel preoperative risk score to optimize patient selection for performing concomitant liver resection with cytoreductive surgery/HIPEC. J Surg Oncol 123(1):187-195, 2021. e-Pub 2021. PMID: 33002202.
52. Cata JP, Owusu-Agyemang P, Koyyalagunta D, Corrales G, Feng L, Fournier K. Impact of Ketamine on Opioid Use and Persistent Pain After Cytoreductive Surgery with Hyperthermic Chemotherapy. J Pain Res 14:2433-2439, 2021. e-Pub 2021. PMID: 34413677.
53. Roife D, Powers BD, Zaidi MY, Staley CA, Cloyd JM, Ahmed A, Grotz T, Leiting J, Fournier K, Lee AJ, Veerapong J, Baumgartner JM, Clarke C, Patel SH, Hendrix RJ, Lambert L, Abbott DE, Pokrzywa C, Lee B, Blakely A, Greer J, Johnston FM, Laskowitz D, Dessureault S, Dineen SP. CRS/HIPEC with Major Organ Resection in Peritoneal Mesothelioma Does not Impact Major Complications or Overall Survival: A Retrospective Cohort Study of the US HIPEC Collaborative. Ann Surg Oncol 27(13):4996-5004, 2020. e-Pub 2020. PMID: 33073341.
54. Gamboa AC, Lee RM, Turgeon MK, Zaidi MY, Kimbrough CW, Grotz TE, Leiting J, Fournier K, Lee AJ, Dineen SP, Powers BD, Veerapong J, Baumgartner JM, Clarke CN, Mogal H, Patel SH, Lee TC, Lambert LA, Hendrix RJ, Abbott DE, Pokrzywa C, Raoof M, Eng OS, Johnston FM, Greer J, Cloyd JM, Maithel SK, Staley CA. Implications of Postoperative Complications for Survival After Cytoreductive Surgery and HIPEC: A Multi-Institutional Analysis of the US HIPEC Collaborative. Ann Surg Oncol 27(13):4980-4995, 2020. e-Pub 2020. PMID: 32696303.
55. Kubi B, Gunn J, Fackche N, Cloyd JM, Abdel-Misih S, Grotz T, Leiting J, Fournier K, Lee AJ, Dineen S, Dessureault S, Veerapong J, Baumgartner JM, Clarke C, Mogal H, Patel SH, Dhar V, Lambert L, Hendrix RJ, Abbott DE, Pokrzywa C, Raoof M, Lee B, Maithel SK, Staley CA, Johnston FM, Wang NY, Greer JB. Predictors of Nonhome Discharge after Cytoreductive Surgery and HIPEC. J Surg Res 255:475-485, 2020. e-Pub 2020. PMID: 32622162.
56. Raghav K, Shen JP, Jácome AA, Guerra JL, Scally CP, Taggart MW, Foo WC, Matamoros A, Shaw KR, Fournier K, Overman MJ, Eng C. Integrated clinico-molecular profiling of appendiceal adenocarcinoma reveals a unique grade-driven entity distinct from colorectal cancer. Br J Cancer 123(8):1262-1270, 2020. e-Pub 2020. PMID: 32733093.
57. Eng OS, Blakely AM, Lafaro KJ, Fournier KF, Fackche NT, Johnston FM, Dineen S, Powers B, Hendrix R, Lambert LA, Ronnekleiv-Kelly S, Walle KV, Grotz TE, Leiting JL, Patel SH, Dhar VK, Baumgartner JM, Lowy AM, Clarke CN, Mogal H, Zaidi MY, Staley CA, Kimbrough C, Cloyd JM, Lee B, Raoof M. Institutional variation in recovery after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: An opportunity for enhanced recovery pathways. J Surg Oncol 122(5):980-985, 2020. e-Pub 2020. PMID: 32627199.
58. Leiting JL, Cloyd JM, Ahmed A, Fournier K, Lee AJ, Dessureault S, Felder S, Veerapong J, Baumgartner JM, Clarke C, Mogal H, Staley CA, Zaidi MY, Patel SH, Ahmad SA, Hendrix RJ, Lambert L, Abbott DE, Pokrzywa C, Raoof M, LaRocca CJ, Johnston FM, Greer J, Grotz TE. Comparison of open and closed hyperthermic intraperitoneal chemotherapy: Results from the United States hyperthermic intraperitoneal chemotherapy collaborative. World J Gastrointest Oncol 12(7):756-767, 2020. e-Pub 2020. PMID: 32864043.
59. Beal EW, Suarez-Kelly LP, Kimbrough CW, Johnston FM, Greer J, Abbott DE, Pokrzywa C, Raoof M, Lee B, Grotz TE, Leiting JL, Fournier K, Lee AJ, Dineen SP, Powers B, Veerapong J, Baumgartner JM, Clarke C, Mogal H, Russell MC, Zaidi MY, Patel SH, Dhar V, Lambert L, Hendrix RJ, Hays J, Abdel-Misih S, Cloyd JM. Impact of Neoadjuvant Chemotherapy on the Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: A Multi-Institutional Retrospective Review. J Clin Med 9(3), 2020. e-Pub 2020. PMID: 32164300.
60. Lee RM, Zaidi MY, Gamboa AC, Speegle S, Kimbrough CW, Cloyd JM, Leiting JL, Grotz TE, Lee AJ, Fournier KF, Powers BD, Dineen SP, Baumgartner J, Veerapong J, Clarke CN, Sussman JJ, Patel S, Hendrix RJ, Lambert LA, Vande Walle KA, Abbott DE, LaRocca CJ, Raoof M, Fackche N, Johnston FM, Staley CA, Maithel SK, Russell MC. What is the Optimal Preoperative Imaging Modality for Assessing Peritoneal Cancer Index? An Analysis From the United States HIPEC Collaborative. Clin Colorectal Cancer 19(1):e1-e7, 2020. e-Pub 2020. PMID: 31974019.
61. Snyder RA, Fournier K, Royal R, Venook AP, Chang GJ. Heated Intraperitoneal Chemotherapy for Colorectal Carcinomatosis: Emerging Evidence. Clin Colorectal Cancer 19(1):1-4, 2020. e-Pub 2020. PMID: 31983613.
62. Wiseman JT, Kimbrough C, Beal EW, Zaidi MY, Staley CA, Grotz T, Leiting J, Fournier K, Lee AJ, Dineen S, Powers B, Veerapong J, Baumgartner JM, Clarke C, Patel SH, Dhar V, Hendrix RJ, Lambert L, Abbott DE, Pokrzywa C, Raoof M, Lee B, Fackche N, Greer J, Pawlik TM, Abdel-Misih S, Cloyd JM. Predictors of Anastomotic Failure After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Does Technique Matter?. Ann Surg Oncol 27(3):783-792, 2020. e-Pub 2020. PMID: 31659645.
63. Beal EW, Ahmed A, Grotz T, Leiting J, KF F, Lee AJ, Dineen S, Dessureault S, Baumgartner JM, Veerapong J, Clarke C, Strong E, Maithel SK, Zaidi MY, Patel S, Dhar V, Hendrix R, Lambert L, Johnston F, Fackche N, Raoof M, LaRocca C, Ronnekleiv-Kelly S, Pokrzywa C, Pawlik TM, Abdel-Misih S, Cloyd JM. Trends in the indications for and short-term outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Am J Surg 219(3):478-483, 2020. e-Pub 2020. PMID: 31558307.
64. Lee TC, Wima K, Sussman JJ, Ahmad SA, Cloyd JM, Ahmed A, Fournier K, Lee AJ, Dineen S, Powers B, Veerapong J, Baumgartner JM, Clarke C, Mogal H, Zaidi MY, Maithel SK, Leiting J, Grotz T, Lambert L, Hendrix RJ, Abbott DE, Pokrzywa C, Blakely AM, Lee B, Johnston FM, Greer J, Patel SH. Readmissions After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: a US HIPEC Collaborative Study. J Gastrointest Surg 24(1):165-176, 2020. e-Pub 2020. PMID: 31745888.
65. Zaidi MY, Lee RM, Gamboa AC, Speegle S, Cloyd JM, Kimbrough C, Grotz T, Leiting J, Fournier K, Lee AJ, Dineen S, Dessureault S, Kelly KJ, Kotha NV, Clarke C, Gamblin TC, Patel SH, Lee TC, Hendrix RJ, Lambert L, Ronnekleiv-Kelly S, Pokrzywa C, Blakely AM, Lee B, Johnston FM, Fackche N, Russell MC, Maithel SK, Staley CA. Preoperative Risk Score for Predicting Incomplete Cytoreduction: A 12-Institution Study from the US HIPEC Collaborative. Ann Surg Oncol 27(1):156-164, 2020. e-Pub 2020. PMID: 31602579.
66. Levinsky NC, Morris MC, Wima K, Sussman JJ, Ahmad SA, Cloyd JM, Kimbrough C, Fournier K, Lee A, Dineen S, Dessureault S, Veerapong J, Baumgartner JM, Clarke C, Zaidi MY, Staley CA, Maithel SK, Leiting J, Grotz T, Lambert L, Hendrix RJ, Ronnekleiv-Kelly S, Pokrzywa C, Raoof M, Eng OS, Johnston FM, Greer J, Patel SH. Should We Be Doing Cytoreductive Surgery with HIPEC for Signet Ring Cell Appendiceal Adenocarcinoma? A Study from the US HIPEC Collaborative. J Gastrointest Surg 24(1):155-164, 2020. e-Pub 2020. PMID: 31428960.
67. Leiting JL, Day CN, Harmsen WS, Cloyd JM, Abdel-Misih S, Fournier K, Lee AJ, Dineen S, Dessureault S, Veerapongh J, Baumgartner JM, Clarke C, Mogal H, Russell MC, Zaidi MY, Patel SH, Morris MC, Hendrix RJ, Lambert LA, Abbott DE, Pokrzywa C, Raoof M, Eng O, Johnston FM, Greer J, Grotz TE. The impact of HIPEC vs. EPIC for the treatment of mucinous appendiceal carcinoma: a study from the US HIPEC collaborative. Int J Hyperthermia 37(1):1182-1188, 2020. e-Pub 2020. PMID: 33040617.
68. Ikoma N, Estrella JS, Hofstetter WL, Ajani JA, Fournier KF, Mansfield PF, Skibber JM, Badgwell BD. Surgeon Assessment of Gastric Cancer Lymph Node Specimens with a Video of Technique. J Gastrointest Surg 22(11):2013-2019, 2018. e-Pub 2018. PMID: 30054780.
69. Ikoma N, Das P, Hofstetter W, Ajani JA, Estrella JS, Chen HC, Wang X, Callender RA, Zhu C, Roland CL, Fournier KF, Cormier JN, Mansfield P, Badgwell BD. Preoperative chemoradiation therapy induces primary-tumor complete response more frequently than chemotherapy alone in gastric cancer: analyses of the National Cancer Database 2006-2014 using propensity score matching. Gastric Cancer 21(6):1004-1013, 2018. e-Pub 2018. PMID: 29730720.
70. Ikoma N, Estrella JS, Hofstetter W, Das P, Minsky BD, Ajani JA, Fournier KF, Mansfield P, Badgwell BD. Nodal Downstaging in Gastric Cancer Patients: Promising Survival if ypN0 is Achieved. Ann Surg Oncol 25(7):2012-2017, 2018. e-Pub 2018. PMID: 29748883.
71. Ikoma N, Hofstetter WL, Estrella JS, Das P, Minsky BD, Fournier KF, Mansfield PF, Ajani JA, Badgwell BD. The ypT category does not impact overall survival in node negative gastric cancer. J Surg Oncol 117(8):1721-1728, 2018. e-Pub 2018. PMID: 29949666.
72. Hayes-Jordan AA, Coakley BA, Green HL, Xiao L, Fournier KF, Herzog CE, Ludwig JA, McAleer MF, Anderson PM, Huh WW. Desmoplastic Small Round Cell Tumor Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Results of a Phase 2 Trial. Ann Surg Oncol 25(4):872-877, 2018. e-Pub 2018. PMID: 29383611.
73. Ikoma N, Blum M, Estrella JS, Das P, Hofstetter WL, Fournier KF, Mansfield P, Ajani JA, Badgwell BD. Evaluation of the American Joint Committee on Cancer 8th edition staging system for gastric cancer patients after preoperative therapy. Gastric Cancer 21(1):74-83, 2018. e-Pub 2018. PMID: 28643144.
74. Dineen SP, Royal RE, Mansfield PF, Fournier KF. Comment on: External Validation of the Simplified Preoperative Assessment for Low-Grade Mucinous Adenocarcinoma of the Appendix. Ann Surg Oncol 24(Suppl 3):627, 2017. e-Pub 2017. PMID: 29124485.
75. Sagebiel TL, Mohamed A, Matamoros A, Taggart MW, Doamekpor F, Raghav KP, Mann GN, Mansfield PF, Eng C, Royal RE, Foo WC, Ensor JE, Fournier KF, Overman MJ. Utility of Appendiceal Calcifications Detected on Computed Tomography as a Predictor for an Underlying Appendiceal Epithelial Neoplasm. Ann Surg Oncol 24(12):3667-3672, 2017. e-Pub 2017. PMID: 28831698.
76. Ikoma N, Blum M, Estrella JS, Wang X, Fournier KF, Mansfield PF, Ajani JA, Badgwell BD. Left Gastric Artery Lymph Nodes Should Be Included in D1 Lymph Node Dissection in Gastric Cancer. J Gastrointest Surg 21(10):1563-1570, 2017. e-Pub 2017. PMID: 28819789.
77. Grotz TE, Royal RE, Mansfield PF, Overman MJ, Mann GN, Robinson KA, Beaty KA, Rafeeq S, Matamoros A, Taggart MW, Fournier KF. Stratification of outcomes for mucinous appendiceal adenocarcinoma with peritoneal metastasis by histological grade. World J Gastrointest Oncol 9(9):354-362, 2017. e-Pub 2017. PMID: 28979717.
78. Grotz TE, Overman MJ, Eng C, Raghav KP, Royal RE, Mansfield PF, Mann GN, Robinson KA, Beaty KA, Rafeeq S, Matamoros A, Taggart MW, Fournier KF. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Moderately and Poorly Differentiated Appendiceal Adenocarcinoma: Survival Outcomes and Patient Selection. Ann Surg Oncol 24(9):2646-2654, 2017. e-Pub 2017. PMID: 28695394.
79. Uemura M, Qiao W, Fournier K, Morris J, Mansfield P, Eng C, Royal RE, Wolff RA, Raghav K, Mann GN, Overman MJ. Retrospective study of nonmucinous appendiceal adenocarcinomas: role of systemic chemotherapy and cytoreductive surgery. BMC Cancer 17(1):331, 2017. e-Pub 2017. PMID: 28506255.
80. Ikoma N, Blum M, Chiang YJ, Estrella JS, Roy-Chowdhuri S, Fournier K, Mansfield P, Ajani J, Badgwell BD. Race Is a Risk for Lymph Node Metastasis in Patients With Gastric Cancer. Ann Surg Oncol 24(4):960-965, 2017. e-Pub 2017. PMID: 27778127.
81. Fournier K, Rafeeq S, Taggart M, Kanaby P, Ning J, Chen HC, Overman M, Raghav K, Eng C, Mansfield P, Royal R. Low-grade Appendiceal Mucinous Neoplasm of Uncertain Malignant Potential (LAMN-UMP): Prognostic Factors and Implications for Treatment and Follow-up. Ann Surg Oncol 24(1):187-193, 2017. e-Pub 2017. PMID: 27660258.
82. Ikoma N, Blum M, Chiang YJ, Estrella JS, Roy-Chowdhuri S, Fournier K, Mansfield P, Ajani JA, Badgwell BD. Yield of Staging Laparoscopy and Lavage Cytology for Radiologically Occult Peritoneal Carcinomatosis of Gastric Cancer. Ann Surg Oncol 23(13):4332-4337, 2016. e-Pub 2016. PMID: 27384751.
83. Grotz TE, Mansfield PF, Royal RE, Mann GN, Rafeeq S, Beaty KA, Overman MJ, Fournier KF. Intrathoracic Chemoperfusion Decreases Recurrences in Patients with Full-Thickness Diaphragm Involvement with Mucinous Appendiceal Adenocarcinoma. Ann Surg Oncol 23(9):2914-9, 2016. e-Pub 2016. PMID: 27027310.
84. Owusu-Agyemang P, Cata JP, Fournier KF, Zavala AM, Soliz J, Hernandez M, Hayes-Jordan A, Gottumukkala V. Evaluating the Impact of Total Intravenous Anesthesia on the Clinical Outcomes and Perioperative NLR and PLR Profiles of Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy. Ann Surg Oncol 23(8):2419-29, 2016. e-Pub 2016. PMID: 26975738.
85. Ikoma N, Blum M, Chiang YJ, Estrella JS, Roy-Chowdhuri S, Fournier K, Mansfield P, Ajani JA, Badgwell BD. Survival rates in T1 and T2 gastric cancer: A Western report. J Surg Oncol. e-Pub 2016. PMID: 27439746.
86. Day RW, Badgwell BD, Fournier KF, Mansfield PF, Aloia TA. Defining the Impact of Surgical Approach on Perioperative Outcomes for Patients with Gastric Cardia Malignancy. J Gastrointest Surg 20(1):146-53; discussion 153, 2016. e-Pub 2016. PMID: 26416411.
87. Dineen SP, Robinson KA, Roland CL, Beaty KA, Rafeeq S, Mansfield PF, Royal RE, Fournier KF. Feeding tube placement during cytoreductive surgery and heated intraperitoneal chemotherapy does not improve postoperative nutrition and is associated with longer length of stay and higher readmission rates. J Surg Res 200(1):158-63, 2016. e-Pub 2016. PMID: 26342838.
88. Badgwell B, Ajani J, Blum M, Ho L, Fournier K, Chiang YJ, Matamoros A, Das P, Mansfield P. Postoperative Morbidity and Mortality Rates are Not Increased for Patients with Gastric and Gastroesophageal Cancer Who Undergo Preoperative Chemoradiation Therapy. Ann Surg Oncol 23(1):156-62, 2016. e-Pub 2016. PMID: 26059652.
89. Dineen SP, Royal RE, Hughes MS, Sagebiel T, Bhosale P, Overman M, Matamoros A, Mansfield PF, Fournier KF. A Simplified Preoperative Assessment Predicts Complete Cytoreduction and Outcomes in Patients with Low-Grade Mucinous Adenocarcinoma of the Appendix. Ann Surg Oncol 22(11):3640-6, 2015. e-Pub 2015. PMID: 25698402.
90. Choe JH, Overman MJ, Fournier KF, Royal RE, Ohinata A, Rafeeq S, Beaty K, Phillips JK, Wolff RA, Mansfield PF, Eng C. Improved Survival with Anti-VEGF Therapy in the Treatment of Unresectable Appendiceal Epithelial Neoplasms. Ann Surg Oncol 22(8):2578-84, 2015. e-Pub 2015. PMID: 25582740.
91. Badgwell B, Blum M, Estrella J, Chiang YJ, Das P, Matamoros A, Fournier K, Mansfield P, Ajani J. Predictors of Survival in Patients with Resectable Gastric Cancer Treated with Preoperative Chemoradiation Therapy and Gastrectomy. J Am Coll Surg 221(1):83-90, 2015. e-Pub 2015. PMID: 26002780.
92. Badgwell B, Roy-Chowdhuri S, Chiang YJ, Matamoros A, Blum M, Fournier K, Mansfield P, Ajani J. Long-term survival in patients with metastatic gastric and gastroesophageal cancer treated with surgery. J Surg Oncol 111(7):875-81, 2015. e-Pub 2015. PMID: 25872485.
93. Bertrand AM, Fournier K, Wick Brasey MG, Kaiser ML, Frischknecht R, Diserens K. Reliability of maximal grip strength measurements and grip strength recovery following a stroke. J Hand Ther. e-Pub 2015. PMID: 26206167.
94. Overman MJ, Eng C, Raghav K, Matamoros A, Taggart M, Foo WC, Fournier K. Challenges of efficacy assessments in pseudomyxoma peritonea. Oncologist 20(3):e3-4, 2015. e-Pub 2015. PMID: 25745054.
95. Zitomersky NL, Atkinson BJ, Fournier K, Mitchell PD, Stern JB, Butler MC, Ashworth L, Hauenstein S, Heiner L, Chuang E, Singh S, Bousvaros A. Antibodies to infliximab are associated with lower infliximab levels and increased likelihood of surgery in pediatric IBD. Inflamm Bowel Dis 21(2):307-14, 2015. e-Pub 2015. PMID: 25569737.
96. Hayes-Jordan A, Green HL, Lin H, Owusu-Agyemang P, Fitzgerald N, Arunkumar R, Mejia R, Okhuysen-Cawley R, Mauricio R, Fournier K, Ludwig J, Anderson P. Complete Cytoreduction and HIPEC Improves Survival in Desmoplastic Small Round Cell Tumor. Ann Surg Oncol 21(1):220-4, 2014. e-Pub 2014. PMID: 24046124.
97. Roses RE, Tzeng CW, Ross MI, Fournier KF, Abbott DE, You YN. The palliative index: predicting outcomes of emergent surgery in patients with cancer. J Palliat Med 17(1):37-42, 2014. e-Pub 2014. PMID: 24410420.
98. Turaga K, Levine E, Barone R, Sticca R, Petrelli N, Lambert L, Nash G, Morse M, Adbel-Misih R, Alexander HR, Attiyeh F, Bartlett D, Bastidas A, Blazer T, Chu Q, Chung K, Dominguez-Parra L, Espat NJ, Foster J, Fournier K, Garcia R, Goodman M, Hanna N, Harrison L, Hoefer R, Holtzman M, Kane J, Labow D, Li B, Lowy A, Mansfield P, Ong E, Pameijer C, Pingpank J, Quinones M, Royal R, Salti G, Sardi A, Shen P, Skitzki J, Spellman J, Stewart J, Esquivel J. Consensus Guidelines from The American Society of Peritoneal Surface Malignancies on Standardizing the Delivery of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Colorectal Cancer Patients in the United States. Ann Surg Oncol 21(5):1501-5, 2014. e-Pub 2014. PMID: 23793364.
99. Wisniewski WR, Fournier KF, Ling YK, Slack RS, Babiera G, Grubbs EG, Moore LJ, Fleming JB, You YN. A focused curriculum in surgical oncology for the third-year medical students. J Surg Res 185(2):555-60, 2013. e-Pub 2013. PMID: 23845865.
100. Taggart MW, Galbincea J, Mansfield PF, Fournier KF, Royal RE, Overman MJ, Rashid A, Abraham SC. High-level Microsatellite Instability in Appendiceal Carcinomas. Am J Surg Pathol 37(8):1192-200, 2013. e-Pub 2013. PMID: 23648460.
101. Overman MJ, Fournier K, Hu CY, Eng C, Taggart M, Royal R, Mansfield P, Chang GJ. Improving the AJCC/TNM staging for adenocarcinomas of the appendix: the prognostic impact of histological grade. Ann Surg 257(6):1072-8, 2013. e-Pub 2013. PMID: 23001080.
102. Bilen MA, Taggart MW, Fournier K, Ellis LM, Mansfield PF, Eng C, Royal RE, Overman MJ. Pathologic complete response in poorly differentiated adenocarcinomas of the appendix: a case series. Acta Oncol 52(5):1044-6, 2013. e-Pub 2013. PMID: 23020527.
103. Hsu C, Rashid A, Xing Y, Chiang YJ, Chagpar RB, Fournier KF, Chang GJ, You YN, Feig BW, Cormier JN. Varying malignant potential of appendiceal neuroendocrine tumors: importance of histologic subtype". J Surg Oncol 107(2):136-43, 2013. e-Pub 2013. PMID: 22767417.
104. Raghav KP, Shetty AV, Kazmi SM, Zhang N, Morris J, Taggart M, Fournier K, Royal R, Mansfield P, Eng C, Wolff RA, Overman MJ. Impact of molecular alterations and targeted therapy in appendiceal adenocarcinomas. Oncologist 18(12):1270-7, 2013. e-Pub 2013. PMID: 24149137.
105. Lieu CH, Lambert LA, Wolff RA, Eng C, Zhang N, Wen S, Rafeeq S, Taggart M, Fournier K, Royal R, Mansfield P, Overman MJ. Systemic chemotherapy and surgical cytoreduction for poorly differentiated and signet ring cell adenocarcinomas of the appendix. Ann Oncol 23(3):652-8, 2012. e-Pub 2012. PMID: 21653683.
106. Suzuki A, Xiao L, Taketa T, Blum MA, Matamoros A, Chien PL, Mansfield PF, Fournier KF, Weston B, Lee JH, Bhutani MS, Estrella JS, Delclos ME, Krishnan S, Das P, Ajani JA. Localized gastric cancer treated with chemoradation without surgery: UTMD Anderson Cancer Center experience. Oncology 82(6):347-51, 2012. e-Pub 2012. PMID: 22677933.
107. Bartley AN, Rashid A, Fournier KF, Abraham SC. Neuroendocrine and mucinous differentiation in signet ring cell carcinoma of the stomach: Evidence for a common cell of origin in composite tumors. Hum Pathol 42(10):1420-9, 2011. e-Pub 2011. PMID: 21419473.
108. Raghav KP, Taggart MW, Fournier KF, Overman MJ. Is malignant dedifferentiation for mucinous appendiceal neoplasms a valid phenomenon or merely histopathologic ambiguity?. J Am Coll Surg 212(5):212(5):906, 2011. e-Pub 2011. PMID: 21530846.
109. Arumugam T, Ramachandran V, Fournier KF, Wang H, Marquis L, Abbruzzese JL, Gallick GE, Logsdon CD, McConkey DJ, Choi W. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res 69(14):5820-8, 2009. e-Pub 2009. PMID: 19584296.
110. Shin S, Fournier K, Cole C, Laronga C. Effect of Sentinel Lymph Node Biopsy on surgical residency training. American Surgeon(72 9):791-795, 2006. e-Pub 2006. PMID: 16966388.
111. Yang H, Zhang Y, Zhao R, Fournier K, Wu HB, Yang HY, Diaz J, Laronga C, Lee MH. Negative cell cycle regulator 14-3-3sigma stabilizes p27 Kip 1 by inhibiting the activity of PKB/Akt. Oncogene. Oncogene(25 33):4585-94, 2006. e-Pub 2006.
112. Yang H, Wen Y, Zhao R, Lin Y, Fournier K, Yang H, Qui Y, Diaz J, Laronga C, Lee M. DNA Damage Induced Protein 14-3-3 Sigma Inhibits Protein Kinase B/Akt Activation and Suppresses Akt-Activated Cancer. Cancer Research(66 6):3096-105, 2006. e-Pub 2006. PMID: 16540659.
113. Fournier K, Schiller A, Perry RR, Laronga C. Micrometastasis in the sentinel lymph node of breast cancer does not mandate completion axillary node dissection. Annals of Surgery(859-63):859-63; discussion 863-5, 2004. e-Pub 2004. PMID: 15166965.
114. Vlahou A, Laronga C, Wilson L, Gregory B, Fournier K, McGaughey D, Perry R, Wright Jr G, Semmes O. A Novel Approach Towards Development of a Rapid Blood Test for Breast Cancer. Clinical Breast Cancer 4(3):203-209, 2003. e-Pub 2003. PMID: 14499014.
115. Fournier K, Marquis L, Choi W, McConkey D. Histone Deacetylase (HDAC) Inhibitors Increase Chemosensitivity in Pancreatic Cancer Cell Lines. Cancer Research.
116. Overman MJ, Fournier K, Hu CY, Wolff RA, Eng C, Taggart M, Royal R, Mansfield P, Chang GJ. Differential Prognostic Impact of Histological Grade for Mucinous and Non-mucinous Adenocarcinomas of the Appendix: Analysis of the Surveillance, Epidemiology and End Results (SEER) Database. JNCI.

Invited Articles

1. Ajani JA, Das P, Fournier K, Lee JH, Lee J. Early and intermediate stage gastric cancer. Onc Olog 56(8):4-8, 2011. e-Pub 2011.
2. Choi W, Fournier K, McConkey D, Logsdon C, Arumagam T. Identification of epithelial to mesenchymal transition in multidrug resistant pancreatic cancer. Cancer Research(24 22):5183-92, 2004. e-Pub 2004. PMID: 15175388.

Review Articles

1. Ramirez MF, Guerra-Londono JJ, Owusu-Agyemang P, Fournier K, Guerra-Londono CE. Temperature management during cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Front Oncol 12:1062158, 2022. e-Pub 2022. PMID: 36741691.
2. Grotz TE, Fournier KF, Mansfield PF. Patient Selection for Cytoreductive Surgery. Surg Oncol Clin N Am 27(3):443-462, 2018. e-Pub 2018. PMID: 29935682.

Professional Educational Materials

1. . Hyperthermic Intraperitoneal Chemotherapy Manual For Patients.
2. . Cytoreductive surgery/HIPEC Manual for Rotating Residents and Fellows.

Editorials

1. Malpica A, Euscher ED, Marques-Piubelli ML, Ferrufino-Schmidt MC, Miranda RN, Sams R, Royal RE, Raghav KPS, Fournier KF, Ramalingam P. Malignant Mesothelioma of the Peritoneum in Women: A Clinicopathologic Study of 164 Cases. Am J Surg Pathol 45(1):45-58, 2021. PMID: 32769428.
2. Turgeon MK, Gamboa AC, Lee RM, Zaidi MY, Kimbrough C, Grotz T, Fournier K, Powers B, Dineen S, Veerapong J, Clarke C, Mogal H, Patel SH, Lambert L, Ronnekleiv-Kelly S, Raoof M, Fackche N, Greer JB, Staley CA, Cloyd JM, Maithel SK, Winer JH. The Intersection of Age and Tumor Biology with Postoperative Outcomes in Patients After Cytoreductive Surgery and HIPEC. Ann Surg Oncol 27(13):4894-4907, 2020. PMID: 32378087.
3. Powers BD, Felder S, Veerapong J, Baumgartner JM, Clarke C, Mogal H, Staley CA, Maithel SK, Patel S, Dhar V, Lambert L, Hendrix RJ, Abbott DE, Pokrzywa C, Raoof M, Lee B, Johnston FM, Greer J, Cloyd JM, Kimbrough C, Grotz T, Leiting J, Fournier K, Lee AJ, Imanirad I, Dessureault S, Dineen SP. Repeat Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Is Not Associated with Prohibitive Complications: Results of a Multiinstitutional Retrospective Study. Ann Surg Oncol 27(13):4883-4891, 2020. PMID: 32318945.
4. Gamboa AC, Zaidi MY, Lee RM, Speegle S, Switchenko JM, Lipscomb J, Cloyd JM, Ahmed A, Grotz T, Leiting J, Fournier K, Lee AJ, Dineen S, Powers BD, Lowy AM, Kotha NV, Clarke C, Gamblin TC, Patel SH, Lee TC, Lambert L, Hendrix RJ, Abbott DE, Vande Walle K, Lafaro K, Lee B, Johnston FM, Greer J, Russell MC, Staley CA, Maithel SK. Optimal Surveillance Frequency After CRS/HIPEC for Appendiceal and Colorectal Neoplasms: A Multi-institutional Analysis of the US HIPEC Collaborative. Ann Surg Oncol 27(1):134-146, 2020. PMID: 31243668.
5. Kotha NV, Baumgartner JM, Veerapong J, Cloyd JM, Ahmed A, Grotz TE, Leiting JL, Fournier K, Lee AJ, Dineen SP, Dessureault S, Clarke C, Mogal H, Zaidi MY, Russell MC, Patel SH, Sussman JJ, Dhar V, Lambert LA, Hendrix RJ, Abbott DE, Pokrzywa C, Lafaro K, Lee B, Greer JB, Fackche N, Lowy AM, Kelly KJ. Primary Tumor Sidedness is Predictive of Survival in Colon Cancer Patients Treated with Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy: A US HIPEC Collaborative Study. Ann Surg Oncol 26(7):2234-2240, 2019. PMID: 31016486.
6. Overman MJ, Eng C, Raghav K, Matamoros A, Taggart M, Foo WC, Fournier KF. Challenges of efficacy assessments in pseudomyxoma peritoneal. The Oncologist:20:1-2, 2015.
7. Ajani JA, Blum MA, Estrella JS, Das P, Fournier KF. Gastric cancer: apples will always be apples. J Clin Oncol 30(30(9)):1017-8, 2012. PMID: 22331947.
8. Rhagav KP, Taggart M, Fournier K, Overmn MJ. Is malignant dedifferentiation for mucinous appendicle neoplasms a valid phenomenon or merely histopathologic ambiguity. J Am Coll Surg 212(5):906, 2011.

Abstracts

1. Mohammad AZ, Fadl AZ, Saikat C, Yousef A, Overman M, White M, Uppal A, Newhook T, Dasari A, Fournier K. Measurement of circulating tumor DNA (ctDNA) in appendiceal adenocarcinoma (AA): Prevalence, predictors, and correlation with clinical outcome. ESMO Annual 2022 33(4), 2022. e-Pub 2022.
2. Shen J, Yousef F, Zeineddine A, Slack Tidwell R, Wolff R, Taggart M, Uppal A, Rafeeq S, Mansfield P, Raghav K, Overman M, Fournier K. Outcomes of randomized crossover trial of systemic chemotherapy in patients with low-grade mucinous appendiceal adenocarcinoma. ESMO Annual 2022 33(4), 2022. e-Pub 2022.
3. Ito I, White M, Yousef A, Dickson P, Gu Y, Fournier K, Shen J. Orthotopic patient-derived xenograft models of appendiceal adenocarcinoma identify intraperitoneal paclitaxel treatment as an active therapeutic agent. AACR Annual 2022 82(12), 2022. e-Pub 2022.
4. White M, Cox D, Robinson K, Kim B, Bhutiani N, Mansfield P, Royal R, Fournier K. Stapled versus hand-sewn intestinal anastomosis in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. SSAT Annual 2022 162(7), 2022. e-Pub 2022.
5. Uppal A, Helmink B, Grotz T, Konishi T, Fournier K, Nguyen S, Taggart M, Shen J, Bednarski B, You YQ, Chang G. What is the risk for peritoneal metastases and survival afterwards in T4 colon cancers?. Annals of Surgical Oncology 29(7), 2022. e-Pub 2022.
6. Guerra-London C, Owusu-Agyemang P, Corrales G, Rofaeil M, Feng L, Fournier K, Cata J. Risk of intraoperative hyperthermia and outcomes in adults undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Annals of Surgery 29(3), 2021. e-Pub 2021.
7. Londono C, Owusu-Agyemang P, Corrales G, Rofaeil M, Feng L, Fournier K, Cata J. Predicting hyperthermia and its effect in patients with peritoneal surface malignancies. Annals of Surgical Oncology 29(6), 2021. e-Pub 2021.
8. Shen J, Chowdhury S, Wu J, Fournier K, Kopetz S, Raghav K. Transcriptional profiling confirms appendiceal adenocarcinoma is distinct from colorectal cancer, in vivo models needed. AACR Special Conference, 2020. e-Pub 2020.
9. Zafar S, Hu C, Helmink B, Scally CP, Bednarski BK, Fournier KF, Chang GJ. Peritoneal Recurrence after Resection for Stage 1-3 Colorectal Cancer-A Popular Analysis. 15th Annual Academic Surgical Congress, 2020. e-Pub 2020.
10. Eng OS, Blakely AM, Lafaro KJ, Fournier KF, Fackche N, Johnston FM, Dineen S, Powers B, Hendrix RJ, Lambert LA, Abbott D, Vande Walle K, Grotz TE, Leiting JL, Patel SH, Dhar VK, Baumgartner JM, Lowy AM, Clarke CN, Mogal H, Zaidi MY, Staley C, Kimbrough C, Cloyd J, Lee B, Raoof. Institutional Variation in Recovery After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: An Opportunity for Enhanced Recovery Pathways. 2019 Society of Surgical Oncology, 2019. e-Pub 2019.
11. Lee A, Chiang Y, Raghav K, Overman M, Eng C, Taggart M, Feig B, Fournier K. Impact of Tumor Grade and Exent of Lymphadenectomy on Survival for Appendix Cancer. 2019 Society of Surgical Oncology, 2019. e-Pub 2019.
12. Ikoma N, Estrella J, Blum M, Das P, Miniski B, Fournier K, Mansfield P, Badgwell B. Tumor Regression Grade in Gastric Cancer After Preoperative Therapy. 2019 Society of Surgical Oncology, 2019. e-Pub 2019.
13. Scally CP, Robinson K, Beaty K, Rafeeq S, Raghav K, Eng C, Overman M, Foo W, Taggart M, Mansfield P, Royal R, Fournier KF. Prognostic Significance of Acellular Mucin in Patients Undergoing Cytoreductive Surgery and HIPEC (CRS/HIPEC) for Appendiceal Neoplasm. 2019 Society of Surgical Oncology, 2019. e-Pub 2019.
14. Kotha NV, Baumgartner J, Veerapong J, Cloyd J, Ahmed A, Grotz TE, Leiting JL, Fournier KF, Lee A, Dineen S, Dessureault S, Clarke CN, Mogal H, Zaidi MY, Russell MC, Patel SH, Sussman JJ, Lambert LA, Hendrix RJ, Abbott D, Pokrzywa C, Lee B, Lafaro KJ, Greer JB, Fackche N, Lowy AM, Kelly KJ. Primary Tumor Sidedness is Predictive of Survival in Colon Cancer Patients Treated with Cytoreductive Surgery with or without Hyperthermic Intraperitoneal Chemotherapy: A Multi-Institutional Collaboative Study. 2019 Society of Surgical Oncology, 2019. e-Pub 2019.
15. Lindberg J, Rafeeq S, Khazi A, Kanaby P, Shayeb O, Al Khafaji J, Beaty K, Mansfield P, Royal R, Fournier K. Palliative Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC) Provides Durable Disease and Acites Control for Patient with Appendiceal Adenocarcinoma with Extensive Peritoneal Metastases. 11th International Workshop on Peritoneal Surface Malignancy, 2018. e-Pub 2018.
16. Robinson K, Fournier K, Cox D, Rafeeq S, Shayeb O, Arrington A, Wray T, Mansfield P, Royal R. Reasons for Hospital Readmission Following Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherpay (CRS/HIPEC). 11th International Workshop on Peritoneal Surface Malignancy, 2018. e-Pub 2018.
17. Beaty K, Royal R, Mansfield P, Fournier K. Late, Rarely Reported Skin Complication After the Use if Hyperthermic Intraperitoneal Chemotherapy in a Female Patient. 11th International Workshop on Peritoneal Surface Malignancy, 2018. e-Pub 2018.
18. Cox D, Robinson K, Rafeeq S, Shayeb O, Hess K, Mansfield P, Royal R, Fournier K. Stapled Versus Hand-Sewn Intestinal Anastomosis in Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherpay (CRS/HIPEC). 11th International Workshop on Peritoneal Surface Malignancy, 2018. e-Pub 2018.
19. Royal R, Robinson K, Cox D, Arrington A, Beaty K, Shayeb O, Rafeeq S, Hayes-Jordan A, Mansfield P, Fournier K. staged CRS/HIPEC: An Approach for Difficult Cases of Indolent Peritoneal Surface Malignancy. 11th International Workshop on Peritoneal Surface Malignancy, 2018. e-Pub 2018.
20. Ikoma N, Elimova E, Blum M, Ajani J, Chiang Y, Fournier K, Mansfield P, Badgwell B. Risk factors for Survival in Early T stage gastric cancer. J Clin Oncol, 2016. e-Pub 2016.
21. Ikoma N, Elimova E, Blum M, Ajani J, Chiang Y, Fournier K, Mansfield P, Badgwell B. Staging laparoscopy with cytology analysis in gastric cancer. J Clin Oncol, 2016. e-Pub 2016.
22. Phuoc V, Royal R, Mansfield P, Overman M, Fournier K. Degree of intraperitoneal hyperthermia during HIPEC predicts overall survival. Ann Surg Oncol, 2016. e-Pub 2016.
23. Ikoma N, Elimova E, Blum M, Ajani J, Chiang Y, Fournier K, Mansfield P, Badgwell B. Yield of staging laparoscopy in gastric cancer. Ann Surg Oncol, 2016. e-Pub 2016.
24. Ikoma N, Elimova E, Blum M, Ajani J, Chiang Y, Fournier K, Mansfield P, Badgwell B. Preoperative accuracy of gastric cancer staging in patient selection for neoadjuvant therapy. J Clin Oncol, 2016. e-Pub 2016.
25. Badgwell B, Blum M, Estrella J, Chiang Y, Das P, Mansfield P, Fournier K, Ajani J. Predictors of survival in patients with resectable gastric cancer treated with neoadjuvant chemoradiation therapy and gastrectomy. Western Surgical Association, 2014. e-Pub 2014.
26. Dineen S, Robinson K, Beaty K, Rafeeq S, Mansfield P, Royal R, Fournier K. Feeding tube placement during HIPEC for Colorectal cancer does not improve post-operative nutrition and is associated with higher readmission rates. Society of Surgical Oncology 3/2015, 2014. e-Pub 2014.
27. Dallas N, Royal R, Mansfield P, Overman M, Fournier K. Evaluation of complication rates in elderly patient undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. 7th Annual International Symposia Regional Cancer Therapies, 2013. e-Pub 2013.
28. Overman M, Fournier K, Hu C, Wolff R, Eng C, Taggar M, Royal R, Mansfield P, Chang G. Improving the AJCC/TNM staging for adenocarcinomas of the appendix: the prognostic impact of histologic grade. J Clin Oncol 257(6):1072-8, 2013. e-Pub 2013.
29. Eng C, Choe J, Overman M, Fournier K, Phillips J, Baum G, Wolff R, Royal R, Mansfield P, Basen-Engquist K. Assessment of the impact of systemic chemotherapy on the quality of life in patients with metastatic unresectable appendiceal epithelial neoplasm. J Clin Oncol suppl 4, 2013. e-Pub 2013.
30. Sagebiel T, Bhosale P, Fournier K, Taggart M, Matamoros A. Appendiceal Cancer: An update on pathology, imaging and therapy. Radiologic Society of North America, 2013. e-Pub 2013.
31. Beaty K, Royal R, Fournier K, Taggart M, Overman M, Phillips J, Rafeeq S, Mansfield P, Wolff R, Eng C. The natural history and role of surgical cytoreduction and systemic chemotherapy in high-grade mucinous adenocarcinomas of the appendix. J Clin Oncol 31(suppl 4), 2013. e-Pub 2013.
32. Overman M, Fournier K, Hu C, Wolff R, Eng C, Taggart M, Royal R, Mansfield P, Chang G. Improving the AJCC/TNM staging system for adenocarcinomas of the appendix: the prognostic impact of histologic grade. J Clin Oncol suppl 4, 2012. e-Pub 2012.
33. Ling Y, Fournier K, Babiera G, Grubbs E, Wagner J, Hogue S, Fleming J, You YN. The Educational Impact Of A 2-Week Surgical Oncology Rotation For Third-Year Medical Students: A Prospective Study. J Surg Res 172(2):191-193, 2012. e-Pub 2012.
34. Hill J, Rafeeq S, Overman M, Lambert L, Katz M, Royal R, Mansfield P, Fournier K. Lymphatic metastasis in well differentiated appendiceal cancer: Prognostic factors and associations with outcome. J Clin Oncol(30):suppl 4; abstr 406, 2012. e-Pub 2012.
35. Hill J, Rafeeq S, Rice D, Overman M, Royal R, Mansfield P, Fournier K. Clinicopathologic Characteristics of Patients with Appendiceal Adenocarcinoma (AA) and Intra-Thoracic Metastasis. J Clin Oncol 30(suppl 4), 2012. e-Pub 2012.
36. Beaty K, Hill J, Rafeeq S, Overman M, Royal R, Mansfield P, Fournier K. CT Imaging Interval After Complete Cytoreductive Surgery / Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Well Differentiated Adenocarcinoma of the Appendix (WDAA). J Clin Oncol 30(suppl 4; abstr 434), 2012. e-Pub 2012.
37. Eng C, Blackham A, Overman M, Fournier K, Royal R, Gajula P, Levine E, Wolff R, Mansfield P. Systemic chemotherapy in the setting of unresectable appendiceal epithelial neoplasms. J Clin Oncol(30):suppl 4; abstr 568, 2012. e-Pub 2012.
38. Eng C, Overman M, Fournier K, Royal R, Ohinata A, Rafeeq S, Phillips J, Wolff R, Mansfield P. Role of biologic therapy in the treatment of unresectable appendiceal epithelial neoplasms (AEN). J Clin Oncol(30):suppl 4; abstr 628, 2012. e-Pub 2012.
39. Raghav K, Kazmi S, Shetty A, Tagart M, Fournier K, Royal R, Mansfield P, Eng C, Wolff R, Overman M. Prognostic and predictive effect of COX-2 expression in appendiceal adenocarcinoma. J Clin Oncol 30(suppl 4), 2012. e-Pub 2012.
40. Tseng WW, Rafeeq S, Beaty K, Mansfield P, Fournier KF, Royal RE. Preoperative Hydration is Essential to Minimize Nephrotoxicity of Cisplatinum-based Hyperthermic Intraperitoneal Chemotherapy, 2011. e-Pub 2011.
41. Fournier K, Royal R, Seigbel T, Matamoris A, Mansfield P. Accurate Preoperative Radiologic Assessment of Complete Cytoreductive Success (PRACS) for Low Grade Mucinous Adenocarcinoma (LGMA) of the Appendix. 5th International symposium on regional cancer therapies, 2011. e-Pub 2011.
42. Fournier K, Royal R, Taggert M, Mansfield P. Mucinous appendiceal tumors of uncertain malignant potential: Implications for treatment and follow-up. GI ASCO, 2011. e-Pub 2011.
43. Fournier K, Royal R, Mansfield P. Impact of Body Mass Index on Outcomes of patients undergoing cytoreductive surgery and Hyperthermic Intraperitoneal chemotherapy. Society of Surgical Oncology, 2010. e-Pub 2010.
44. Hill J, Smith J, Ng S, Lambert L, Mansfield P, Fournier K, Royal R, Cormier J, Tseng J. The surgical treatment of appendiceal cancer in the modern era. Society of Surgical Oncology, 2010. e-Pub 2010.
45. Lambert L, Fournier K, Mansfield P. Hyperthermic intraperitoneal chemotherapy prevents recurrence of mucinous ascites from appendiceal cancer. 5th International symposium on regional cancer therapies, 2010. e-Pub 2010.
46. Lieu C, Lambart L, Wolff R, Eng C, Lin E, Rafeeq S, Fournier K, Royal R, Mansfield P, Overman M. The role of surgical cytoreduction and systemic chemotherapy in metastatic poorly differentiated or signet ring cell adenocarcinomas of the appendix. J Clin Oncol, 2010. e-Pub 2010.
47. Fournier K, Marquis L, Choi W, McConkey D. Histone Deactylase Inhibitors reverse EMT phenotype and chemoresistance in pancreatic cancer cell lines. Molecular Targets and Cancer Therapeutics, 2009. e-Pub 2009.
48. Fournier K, Marquis L, Wray C, McConkey. Restoring E-cadherin Levels Increases Chemosensitivity in Pancreatic Cancer Cell Lines. Society of Surgical Oncology 62nd Annual Cancer Symposium, 2009. e-Pub 2009.
49. Fournier K, Xing Y, Ross M, Lee J, Gershenwald J, Mansfield P, Lucci A, Cormier J. Survival in Patients with Synchronous versus Metachronous Lymph Node (LN) Involvement in Stage III Melanoma: Is There a Difference?. 44th ASCO Annual Meeting, 2008. e-Pub 2008.
50. Sundi D, Fournier K, Wray C, McConkey D. The novel proteasome inhibitor NPI-0052 plus TRAIL activates the extrinsic apoptotic pathway in pancreatic cancer. Society of Surgical Oncology 61st Annual Cancer Symposium, 2008. e-Pub 2008.
51. Wray C, Fournier K, Sundi D, Zhu K, Marquis L, McConkey D. Activation of the unfolded protein response in melanoma cell lines exposed to proteasome inhibitor-induced ER stress. Society of Surgical Oncology 61st Annual Cancer Symposium, 2008. e-Pub 2008.
52. Fournier K, Lambert L, Mansfield P. Do Thrombocytopenia and Coagulopathy Increase the Risks of Central Venous Catheter Insertion. Society of Surgical Oncology 61st Annual Cancer Symposium, 2008. e-Pub 2008.
53. Wray C, Fournier K, Sundi D, Marquis L, McConkey D. Combination proteasome- and histone deacetylase (HDAC) inhibitor treatment of pancreatic cancer. 4th ASCO GI Symposia, 2008. e-Pub 2008.
54. Sundi D, Fournier K, Wray C, Marquis L, McConkey D. Combination treatment of pancreatic cancer cells with NPI-0052 and TRAIL activates heterogeneous apoptotic responses. 4th ASCO GI Symposia, 2008. e-Pub 2008.
55. Fournier K, Wray C, Sundi D, McConkey D. Activation of the Unfolded Protein Response After Exposure to BMS-354825 in Pancreatic Cancer Cell Lines. 4th ASCO GI Symposia, 2008. e-Pub 2008.
56. Shin S, Fournier K, Cole F, Laronga C. Effects of sentinel lymph node biopsy on surgical residency training. Am Surg:791-5; discussion 795-7, 2006. e-Pub 2006. PMID: 16986388.
57. Fournier K, Mosely, Laronga C, Perry R. Stereotactic Breast Biopsy-A Comparison of Surgeons and Radiologists. Society of Surgical Oncology 59th Annual Cancer Symposium. San Diego, 2006. e-Pub 2006.
58. Fournier K, Uroskie T, Colon L, Weiss D, Erb D, Laronga C. Liposuction for Arm Lymphedema After Breast Cancer Surgery. Society of Surgical Oncology 59th Annual Cancer Symposium, 2006. e-Pub 2006.
59. Yang H, Wen YY, Zhao R, Lin YL, Fournier K, Yang HY, Qiu Y, Diaz J, Laronga C, Lee MH. DNA damage-induced protein 14-3-3 sigma inhibits protein kinase B/Akt activation and suppresses Akt-activated cancer. Cancer Res, 2006. e-Pub 2006. PMID: 16540659.
60. Shin S, Fournier K, Schneider H, Cazares L, Semmes OJ, Drake RR, Schiller A, Goffman T, Laronga C. Racial Disparities in Protein Profiles of Breast Cancer Ductal Epithelial Cells/Sera. Virginia Surgical Society, 2005. e-Pub 2005.
61. Shin S, Fournier K, Schneider H, Cazares L, Semmes OJ, Drake RR, Schiller A, Goffman T, Laronga C. Racial Disparities in Protein Profiles of Breast Cancer Ductal Epithelial Cells/Sera. Society of Surgical Oncology 58th Annual Cancer Symposium. Atlanta, 2005. e-Pub 2005.
62. Becker S, Fournier K, Perry R, Laronga C. Racial Disparities in the Era of Sentinel Lymph Node (SLN) Biopsy for Breast Cancer. American Society of Breast Diseases 28th Annual Symposium, Boston, Massachusetts, 2004. e-Pub 2004.
63. Becker S, Cazares L, Fournier K, Perry R, Drake R, Laronga C. A Blood Test to Discriminate Sentinel Lymph Node (SLN) Positive Breast Cancer Using SELDI-TOF (Surface-Enhanced Laser Desorption/Ionization – Time of Flight) Mass Spectrometry. Society of Surgical Oncology 57th Annual Cancer Symposium, 2004. e-Pub 2004.
64. Fournier K, Schiller A, Perry R, Laronga C. Micrometastasis in the Sentinel Node of Breast Cancer Does Not Mandate Completion Axillary Dissection. 115th Annual Session of the Southern Surgical Association, 2003. e-Pub 2003.
65. K, Mendrinos S, Ritchie J, Vlahou A, Gregory B, Schiller A, Perry R, Wright G, Semmes OJ, Drake R, Laronga C. Feasibility of Protein Evaluation of Ductal Lavage Fluid for Breast Diseases. San Antonio Breast Cancer Symposium, San Antonio, Texas, 2003. e-Pub 2003.
66. Becker S, Jennings L, Cazares L, Fournier K, Drake R, Laronga C. “Differentiation of Benign/Normal from Malignant Breast Tissue Using LCM (Laser Capture Microdissection) and SELDI-TOF MS (Surface-Enhanced Laser Desorption / Ionization – Time of Flight Mass Spectrometry). AACR – Advances in Breast Cancer Research: Genetics, 2003. e-Pub 2003.
67. Becker S, Fournier K, Perry R, Laronga C. Racial Disparities in the Era of Sentinel Lymph Node (SLN) Biopsy for Breast Cancer. American College of Surgeons Virginia Chapter 8th Annual Resident Trauma and Cancer Paper Competition, 2003. e-Pub 2003.
68. Becker S, Jennings L, Cazares L, Fournier K, Drake R, Laronga C. Differentiation of Benign/Normal from Malignant Breast Tissue Using LCM (Laser Capture Microdissection) and SELDI-TOF MS (Surface-Enhanced Laser Desorption / Ionization – Time of Flight Mass Spectrometry). AACR – Advances in Breast Cancer Research: Genetics, Biology and Clinical Implications Conference, 2003. e-Pub 2003.
69. Gregory B, Fournier K, Diaz J, Mong-Hong L, Perry R, Laronga C. Correlation of 14-3-3 Sigma Expression with Estrogen, Progesterone, and Her2 Expression in Breast Cancer. 2003 AACR Annual Meeting, 2003. e-Pub 2003.
70. Fournier K, Vlahou A, Gregory B, Schiller A, Kandil T, Perry R, Wright G, Semmes J, Laronga C. Application of SELDI-TOF mass spectrometry to breast ductal lavage fluid. 2003 AACR Annual Meeting, 2003. e-Pub 2003.
71. Fournier K, Schiller A, Perry R, Laronga C. Micrometastasis in the Sentinel Node of Breast Cancer Does Not Mandate Completion Axillary Dissection. Virginia Surgical Society, 2003. e-Pub 2003.
72. Fournier K, Mendoza R, Schiller A, Goffman T, Brown B, Perry R, Laronga C. Her2 Over-Expression in Inflammatory Breast Carcinoma (IBC). Virginia Chapter of the American College of Surgeons, 2003. e-Pub 2003.
73. Fournier K, Vlahou A, Gregory, B, Schiller, A, Kandil T, Perry R, Wright G, Semmes O, Laronga C. Proteomic Patterns of Ductal Lavage Fluid Obtained by SELDI-TOF Mass Spectrometry. American College of Surgeons Virginia Chapter 7th Annual Resident Trauma and Cancer Paper Competition,, 2002. e-Pub 2002.
74. Fournier K, Mendoza R, Schiller A, Goffman T, Brown B, Perry R, Laronga C. Her2 Over-Expression in Inflammatory Breast Carcinoma (IBC). American College of Surgeons Virginia Chapter 7th Annual Resident Trauma and Cancer Paper Competition, 2002. e-Pub 2002.

Book Chapters

1. Lieu C, Fournier K, Overman MJ. Appendiceal Tumors. In: MD Anderson Manual of Medical Oncology. McGraw Hill, 2010.
2. McConkey DJ, Woonyoung C, Fournier K, Marquis L, Ramachandran V, Arumugam T. Molecular characterization of pancreatic cell lines. In: Handbook of Pancreatic Cancer. Springer, 457-469, 2010.
3. Fournier K, Laronga C. Cystosarcoma Phyllodes. In: Advanced Therapy of Breast Diseases. 2nd. B.C. Decker Inc, 700-705, 2004.
4. Dineen S, Mansfield P, Royal R, Fournier K. Management of high grade appendix adenocarcinoma. Intraperitoneal Cancer Therapy. In: Intraperitoneal Cancer Therapy Principals and Practice. CRC.